ArchiveJuly 2018

Oligoclonal bands: what are they doing?

Oligoclonal bands (OB) are a characteristic hallmark of MS. They occur from disease onset. But what are they doing? Despite much wishful thinking by researchers that OB are producing the pathogenic antibody (which they may well do) it has to be said that people have looked and looked, but no consistent antibody has yet been found in MS. However, do the antibodies in the OB have to be specific for...

Guest post: Has the MS Society woken up?

Finally the MS Society is embracing people with progressive MS and mobility issues in a positive way. There will be a walk of one kilometre at the next sponsored walk in Battersea Park on September 2018. Sport is an area of society in which ableism is seen only too often. It is only within the last ten to fifteen years that society no longer perceives athletes with disabilities as being inferior...

Sunday Digest

Here are links to a few papers that some of you may find interesting This is one for the neuros reading or anyone interested in imaging  Arevalo O, Riascos R, Rabiei P, Kamali A, Nelson F. Standardizing Magnetic Resonance Imaging Protocols, Requisitions, and Reports in Multiple Sclerosis: An Update for Radiologist Based on 2017 Magnetic Resonance Imaging in Multiple Sclerosis and 2018...

Newsflash Medical Cannabis to be Legalised in the UK. The value of People power

Today the UK have announced that they plan to legalise cannabis for medical use and so join the Republic of Ireland, Germany, The Netherlands and Israel. Therefore, a new treatment option for symptom control and probably progressive MS (yes a neuroprotective) may be coming your way. Twenty years ago, we (MD1 & MD2) provided the first scientific evidence that the endocannabinoid system...

Stornoway research day series: Holistic care of MS patients

MS specialist nurse Mhairi Coutts discusses the definition of holistic care. She outlines how to use the concept as part of caring for people with MS. She argues that a holistic, multi-disciplinary approach is essential to meeting the needs of patients and caring for them effectively. Watch Mhairi’s talk on our Youtube channel. Subscribe to our channel to keep up to date on our talks and...

Switching from Natalizumab to Fingolimod

People taking natalizumab often have to stop and switch to something else, such as if you are JC virus positive and have been on previous immunosuppression. You don’t want to immunosuppress in case the person has sub clinical PML. You don’t want to wait too long because disease will reactivate. What happens if the time interval is only a month between stopping and starting...

NHS constitution. The DrK Update

This post is for anyone who lives (with MS) in or works (neuros & nurses) in England. This relates t a recent post on the NHS constitution Update: This is a Comment Made by DrK. As many of you don’t read comments I thought I would post this. “Much of what the barrister said should worry neurologists who feel they can stick to the old days, being highly...

NHS Constitution. Will the law change prescribing habits?

Is this you? No I mean You! This post is for anyone who lives (with MS) in or works (neuros & nurses) in England. Also for any Americans, as I know you like your constitution stories:-) If you live in England you must read this Constitution, because it may be the Legal system that changes prescribing habits. Getting rid of smoking in public met resistance, however once Employment...

Stornoway research day series: Treating to a target of NEDA

What is NEDA? Why is it important? Why should healthcare professionals be aiming for it? DrK presents his arguments in this Stornoway research day talk to healthcare professionals. DrK discusses the aim of treating MS until there is no evidence of disease activity (NEDA). He explains NEDA as an evolving concept that is used to influence treatment strategies, as an outcome in trials and as a...

Inspire, expires: The first breath of the Charcot Project

Is MS a problem caused by a virus? Is the world flat? The INSPIRE trial set out to investigate one of these following an anecdote that a person, who had MS but was treated with HIV-inhibiting treatment, did well.  Was this a fluke or the beginning of a new era in MS research? You know the answer. Yep, the trial was not a success. This study looked at raltegravir, rather than looking at...

Translate

Categories

Recent Posts

Recent Comments

Archives